Literature DB >> 22965998

Pre-explant stability of unloading-promoted cardiac improvement predicts outcome after weaning from ventricular assist devices.

Michael Dandel1, Yuguo Weng, Henryk Siniawski, Evgenij Potapov, Thomas Krabatsch, Hans B Lehmkuhl, Thorsten Drews, Christoph Knosalla, Roland Hetzer.   

Abstract

BACKGROUND: Detection of cardiac recovery that allows long-term cardiac stability after ventricular assist device (VAD) explantation is a major goal. After normalization of ventricular diameters during unloading, the pre-explant left ventricular ejection fraction (LVEF) allows the detection of patients with the potential to remain stable after VAD explantation. However, some patients with LVEF >45 before VAD explantation show early recurrence of heart failure (HF). We aimed to find out if unstable improvement can be recognized before VAD explantation. METHODS AND
RESULTS: Among 96 patients weaned from VADs since 1995, a relatively homogenous group of 53 patients with nonischemic chronic cardiomyopathy (CCM) was selected for the study. The pre-explant stability of major parameters of LV function, size, and geometry that were measured by echocardiography during serial "off-pump" trials was tested for relationship with cardiac stability after VAD explantation. LVEF, systolic peak wall motion velocity (Sm), end-diastolic diameter (LVEDD), end-diastolic relative wall thickness (RWT(ED)) and end-diastolic short/long-axis ratio (S/L(ED)) were selected for evaluation. In postweaning unstable patients, the selected parameters showed relevant instability already before VAD explantation during the time period between best cardiac improvement and VAD explantation and also during the final off-pump trial just before VAD explantation. For all parameters, there were significant differences (P<0.05) in pre-explant changes between patients with and without postweaning cardiac stability. Using the optimal cutoff values obtained from receiver-operating characteristic analysis, we found for our selected parameters predictive values for postexplant cardiac stability of ≥1 year, ≥3 years, and ≥5 years, ranging between 94 and 100, 92, and 100, and 78 and 100, respectively. Using for all parameter changes the cutoff value of 10, we found similar predictive values for cardiac stability of ≥1 year, ≥3 years, and ≥5 years, ranging between 93 and 97, 90 and 96, and 83 and 92, respectively.
CONCLUSIONS: Our results strongly suggest the possibility to improve the prediction of postexplant transplant/VAD-free outcome in CCM patients with cardiac improvement during VAD support by analyzing the pre-explant stability of several LV off-pump echocardiographic parameters during serial off-pump trials.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22965998     DOI: 10.1161/CIRCULATIONAHA.111.084640

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

Review 1.  Molecular and cellular basis of viable dysfunctional myocardium.

Authors:  Marina Bayeva; Konrad Teodor Sawicki; Javed Butler; Mihai Gheorghiade; Hossein Ardehali
Journal:  Circ Heart Fail       Date:  2014-07       Impact factor: 8.790

Review 2.  [Ventricular long-term support with implantable continuous flow pumps: on the way to a gold standard in the therapy of terminal heart failure].

Authors:  T Krabatsch; E Potapov; S Soltani; M Dandel; V Falk; C Knosalla
Journal:  Herz       Date:  2015-04       Impact factor: 1.443

Review 3.  Bridge to removal: a paradigm shift for left ventricular assist device therapy.

Authors:  Craig H Selzman; Jesse L Madden; Aaron H Healy; Stephen H McKellar; Antigone Koliopoulou; Josef Stehlik; Stavros G Drakos
Journal:  Ann Thorac Surg       Date:  2014-11-14       Impact factor: 4.330

4.  Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: An IMACS report.

Authors:  D Marshall Brinkley; Li Wang; Chang Yu; E Wilson Grandin; Michael S Kiernan
Journal:  J Heart Lung Transplant       Date:  2021-09-09       Impact factor: 10.247

Review 5.  LVAD as a Bridge to Remission from Advanced Heart Failure: Current Data and Opportunities for Improvement.

Authors:  Christos P Kyriakopoulos; Chris J Kapelios; Elizabeth L Stauder; Iosif Taleb; Rana Hamouche; Konstantinos Sideris; Antigone G Koliopoulou; Michael J Bonios; Stavros G Drakos
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

6.  Magnitude and time course of changes induced by continuous-flow left ventricular assist device unloading in chronic heart failure: insights into cardiac recovery.

Authors:  Stavros G Drakos; Omar Wever-Pinzon; Craig H Selzman; Edward M Gilbert; Rami Alharethi; Bruce B Reid; Abdulfattah Saidi; Nikolaos A Diakos; Sandi Stoker; Erin S Davis; Matthew Movsesian; Dean Y Li; Josef Stehlik; Abdallah G Kfoury
Journal:  J Am Coll Cardiol       Date:  2013-03-14       Impact factor: 24.094

Review 7.  Left ventricular assist device recovery: does duration of mechanical support matter?

Authors:  Binh N Pham; Sandra V Chaparro
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

8.  LVAD decommissioning for myocardial recovery: Long-term ventricular remodeling and adverse events.

Authors:  Eleanor F Gerhard; Lu Wang; Ramesh Singh; Stephan Schueler; Leonard D Genovese; Andrew Woods; Daniel Tang; Nicola Robinson Smith; Mitchell A Psotka; Sian Tovey; Shashank S Desai; Djordje G Jakovljevic; Guy A MacGowan; Palak Shah
Journal:  J Heart Lung Transplant       Date:  2021-08-11       Impact factor: 10.247

9.  Myocardial recovery evaluation from ventricular assist device in patients with dilated cardiomyopathy.

Authors:  Takayuki Gyoten; Eisuke Amiya; Osamu Kinoshita; Masaki Tsuji; Mitsutoshi Kimura; Masaru Hatano; Minoru Ono
Journal:  ESC Heart Fail       Date:  2022-05-10

10.  Myocardial recovery during mechanical circulatory support: cellular, molecular, genomic and organ levels.

Authors:  Michael Dandel; Roland Hetzer
Journal:  Heart Lung Vessel       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.